Potential directions for diagnostic tool development—rapid test kit development: Based on the differential expression of DPP4 and TXN in the blood (with DPP4 highly expressed in the control group and TXN highly expressed in the sepsis group), we plan to collaborate with in vitro diagnostic companies to develop rapid test kits using ELISA or microfluidic technology. Here, TXN is linked to Sepsis.